<DOC>
	<DOCNO>NCT00057460</DOCNO>
	<brief_summary>This study use transcranial magnetic stimulation ( TMS ) electroencephalography ( EEG ) test safety experimental anti-epileptic drug call Talampanel learn affect brain activity . Talampanel block type brain receptor call AMPA ; inhibit receptor may result anti-seizure activity . TMS stimulate out part brain , call cortex . For procedure , insulated wire coil place subject 's scalp . A brief electrical current pass coil , create magnetic pulse stimulate brain . This may cause pull sensation skin coil muscle twitch face , arm , leg . EEG record electrical activity brain , form brain wave . For procedure , electrode ( metal disc conductive gel ) attach wire affixed scalp paste brain activity record . Healthy normal volunteer 18 45 year age may participate study . Candidates screen physical neurological examination , electrocardiogram ( EKG ) , blood test , blood pressure measurement . Women pregnant nursing exclude study . Participants come NIH Clinical Center three test session , least 1 week apart , final follow-up visit . The procedure test session follow : 7 AM - Blood pressure measure , EKG EEC lead place , heparin lock insert , blood sample drawn . The heparin lock thin needle enclose thin plastic tube . The needle guide tube vein remove , leave tube place . The indwell tube allow multiple blood sample draw without repeat needle stick . 8 - 9 AM - TMS follow EEG record . 9 AM - Administration Talampanel placebo ( pill active ingredient ) mouth . 10 AM - Blood sample # 2 . 10 AM -11 AM - TMS , follow EEG record every 5 minute . 11 AM - Blood sample # 3 . 12 PM - Blood sample # 4 . 11 AM - 1 PM - EEG record every 5 minutes/ 4 PM - Blood sample # 5 . 5 PM - Discharge Clinical Center . At final follow-up visit , participant talk doctor one final blood draw .</brief_summary>
	<brief_title>Effect Talampanel ( AMPA Receptor Blocker ) Brain Activity</brief_title>
	<detailed_description>Objectives . The purpose pilot study identify human neurophysiological parameter sensitive talampanel , assess transcranial magnetic stimulation ( TMS ) electroencephalography ( EEG ) . Talampanel highly selective , orally active antagonist AMPA ( alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid ) receptor . The study test two hypothesis : ( 1 ) talampanel , dose-dependent fashion , suppress motor-evoked potential ( MEP ) amplitude intracortical facilitation determine TMS , ( 2 ) talampanel , dose-dependent fashion , cause alteration EEG power within specific frequency band . We plan administer low ( 25 mg ) high ( 50 mg ) dose talampanel placebo normal volunteer measure various TMS EEG parameter hypothesize may influence AMPA receptor blockade . We simultaneously assay serum level talampanel . We use statistical test correlate change TMS EEG measure drug concentration . The result study allow u undertake follow-up study determine effect AMPA receptor blockade talampanel human motor cognitive function . Our ultimate goal determine whether drug-induced blockade AMPA receptor achieve without unacceptable neurological impairment . Study population . This blind placebo-controlled pilot study use 12 normal volunteer . Design . Normal volunteer accept study subject follow exam : ( ) TMS determination MEP amplitude paired-pulse test baseline peak serum level drug placebo administration , ( b ) digital EEG record 1 h baseline administration drug placebo period 3 h administration . Samples serum chemistry , liver function test , hematology , urinalysis obtain admission , discharge , every clinic visit study . Blood sample determine serum talampanel level obtain 1 , 2 , 3 , 8 h drug administration . MEPs interstimulus interval 2 20 m compare among subject drug administration , repeat measure analysis variance . Talampanel level correlate MEP amplitude regression analysis . Clinical endpoint . This pilot study identify information best TMS interstimulus interval interval measure change cortical excitability AMPA blockade , well EEG frequency band sensitive AMPA blockade talampanel . Because talampanel highly selective AMPA receptor antagonist , able infer parameter sensitive talampanel use empirical assay AMPA receptor function human .</detailed_description>
	<criteria>INCLUSION CRITERIA : Study subject must 1845 year old ( inclusive ) . Study subject must give informed consent write prior enter study . Study subject must able participate full term trial . EXCLUSION CRITERIA : Any following condition cause exclusion study : Any illness requiring chronic drug therapy one follow drug : Depakote ( valproic acid ) , Hismanal ( astemizole ) , Propulsid ( cisapride ) , Allegra ( fexofenadine ) , Seldane ( terfenadine ) , Luvox ( fluvoxamine ) , Felbamate ( felbatol ) , Tiagabine ( vigabatrin ) , hepatic enzyme inducer Tagamet ( cimetidine ) , azole antifungal Flagyl ( metronidazole ) , Diflucan ( fluconazole ) , Nizoral ( ketoconazole ) . History psychiatric disorder , care psychiatrist , medication treatment psychiatric disorder . Known sensitivity allergy talampanel related compound . Use illicit drug , binge drinking , alcoholism per medical history inventory . Exposure investigational drug within 12 week prior randomization . Magnetic stimulation perform people pacemaker , implant pumps stimulators , metal object inside eye skull . Being age 18 year age 45 year . Pregnant lactating . Cardiac , pulmonary , neurological problem determine medical history , EKG , examination physician .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2006</verification_date>
	<keyword>Antiepileptic Drug</keyword>
	<keyword>Neuroprotection</keyword>
	<keyword>Seizure Disorder</keyword>
	<keyword>TMS Stimulation</keyword>
	<keyword>EEG</keyword>
	<keyword>AMPA Antagonist</keyword>
	<keyword>Dosing</keyword>
	<keyword>Transcranial Magnetic Stimulation</keyword>
	<keyword>Healthy Volunteer</keyword>
	<keyword>HV</keyword>
</DOC>